Design and preparation method and use of novel and miniaturized car molecule
By designing new miniaturized CAR molecules, combining CD3ζITAM domain and costimulatory molecules, the problems of poor killing effects and side effects of existing CAR-T cells in solid tumors are solved, and efficient and lasting tumor killing effects are achieved.
Patent Information
- Application Number
- PCT/CN2024/095655
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-28
- Publication Date
- 2024-12-05
AI Technical Summary
The existing CAR-T cell therapies have poor killing effects in solid tumors, and the third-generation CAR has increased side effects due to excessive activation. The fourth-generation CAR has not yet verified its clinical effectiveness and safety.
Design a new miniaturized CAR molecule with structures including extracellular segments, transmembrane regions and intracellular segments, with a length of no more than 300 amino acids, and contains a portion of the CD3ζITAM domain, which is used to activate T cell signals and bind to target antigen binding regions. and costimulatory molecules that reduce the risk of signal overactivation.
It significantly improves the killing efficacy and durability of CAR-T cells on tumor cells, has high expression, and the killing activity is 7 times higher when the target ratio is inefficient, with a short starting time, and the use of different hinges or transmembrane regions does not affect the use of Destructive activity.
Smart Images

Figure CN2024095655_05122024_PF_FP_ABST
Abstract
Description
A novel miniaturized CAR molecule design, preparation method and application
[0001] Priority application
[0002] This application claims priority to the Chinese invention patent application [CN202310631350.7] "A new type of CAR-T cell targeting HER2-positive tumors and its preparation method and application" filed on May 31, 2023, which is incorporated by reference in its entirety. Technical Field
[0003] The present invention belongs to the field of molecular cell biology, and specifically relates to a novel miniaturized CAR molecule design, preparation method and application. Background Art
[0004] CAR-T cell therapy (Chimeric Antigen Receptor T-Cell Immunotherapy) is a new, precision-targeted therapy for treating tumors. Research has shown that CAR-T cells can accurately, rapidly, efficiently, and specifically identify and kill tumor cells. In recent years, through optimization and improvement, they have achieved promising results in assisting tumor treatment. It is a highly promising new area of tumor immunotherapy research with the potential to cure cancer. However, controversy remains regarding the effectiveness of CAR-T therapy against various tumors, particularly solid tumors, which present a challenging target for CAR-T therapy.
[0005] Looking at the evolution of CAR molecular design, the first generation of CARs, containing intact CD3ζ or FcRγ signaling domains, was designed in the late 1990s. However, due to suboptimal in vitro durability and persistence, they demonstrated limited or no efficacy in clinical practice. Subsequently, second-generation CARs were developed, featuring a single costimulatory domain in tandem with the CD3ζ intracellular signaling domain. Currently, the two most common costimulatory domains in FDA-approved CAR-T therapeutics are CD28 and 4-1BB (CD137). While second-generation CAR-Ts have demonstrated promising clinical responses primarily in various hematologic malignancies, their efficacy in solid tumors, primarily glioblastoma, advanced sarcomas, liver metastases, and ovarian cancer, has been suboptimal. To further enhance therapeutic efficacy, researchers designed CARs containing two costimulatory domains in tandem with CD3ζ to generate a stronger T cell-stimulating signal, known as third-generation CARs. However, these third-generation CARs have failed to significantly enhance therapeutic efficacy and, in fact, have significantly increased side effects, leading to their demise. Compared to the first three generations of CARs, the fourth-generation CARs add additional regulatory elements (such as cytokine expression elements) to the traditional CAR design to better activate the immune system and enhance anti-tumor activity. However, the fourth-generation CARs are still in the early stages of development, and their clinical efficacy and safety remain to be verified. The development process of the above-mentioned CAR molecular design shows that the CAR molecular structure elements are continuously improved and optimized.
[0006] More studies have found that even minor changes in any part of the CAR structure can affect the anti-tumor activity of CAR-T cells. Specifically, different scFvs, hinge regions, transmembrane regions, costimulatory domains, or ITAMs signaling domains may affect the effectiveness or safety of CAR-T cells. This is because T cells require antigen stimulation to activate and proliferate, but overactivation and excessive affinity for the target can lead to T cell exhaustion and reduced cytotoxic activity, thereby affecting the durability of the CAR-T cell cytotoxic effect.
[0007] In summary, the present invention will provide a novel miniaturized CAR design and CAR-T cells with improved structure to overcome the shortcomings of the existing technology.
[0008] Summary of the Invention
[0009] In view of this, the purpose of the present invention is to provide a novel miniaturized CAR design, preparation method and application, and the specific technical solutions are as follows.
[0010] A novel miniaturized chimeric antigen receptor (CAR) comprises an extracellular segment, a transmembrane region, and an intracellular segment. The extracellular segment comprises an antigen-binding region and a hinge region, and the intracellular segment comprises a portion of CD3ζ in series with a co-stimulatory molecule. The length of the CAR does not exceed 300 amino acids; the length of the antigen-binding region of the extracellular segment does not exceed 150 amino acids; the length of the hinge region and transmembrane region does not exceed 70 amino acids; and the length of the intracellular segment does not exceed 100 amino acids.
[0011] Preferably, the chimeric antigen receptor has a length of 280 to 300 amino acids.
[0012] Furthermore, the part of CD3ζ is the CD3ζ ITAM domain.
[0013] Furthermore, the CD3ζITAM domain includes a CD3ζITAM1 domain, a CD3ζITAM2 domain or a CD3ζITAM3 domain.
[0014] Preferably, further, the partial CD3ζ is the CD3ζ ITAM1 domain, and the nucleotide sequence is shown in SEQ ID NO: 2.
[0015] Furthermore, the antigen binding region is an antibody targeting solid tumors or hematological tumor cell targets.
[0016] Furthermore, the antibody includes a single domain antibody or a nanobody.
[0017] Furthermore, the costimulatory molecule is a single costimulatory molecule.
[0018] Furthermore, the hinge region includes a CD8 hinge region or a CD28 hinge region.
[0019] Furthermore, the transmembrane region includes a CD8 transmembrane region, a CD28 transmembrane region or a CD3 transmembrane region.
[0020] Furthermore, the connection mode of the hinge region and the transmembrane region includes the connection of the CD8 hinge region and the CD8 transmembrane region (8H+8TM), the connection of the CD28 hinge region and the CD28 transmembrane region (28H+28TM), the connection of the CD28 hinge region and the CD3 transmembrane region (28H+3TM), or the connection of the CD8 hinge region and the CD3 transmembrane region (8H+3TM).
[0021] .
[0022] A CAR-T cell expressing the chimeric antigen receptor.
[0023] The use of the above-mentioned CAR-T cells in the preparation of drugs targeting solid tumors or hematological tumors.
[0024] The use of the above-mentioned CAR-T cells in the preparation and treatment of autoimmune diseases.
[0025] Preferably, the solid tumors include target-positive tumors such as ovarian cancer, breast cancer, gastric cancer, intestinal cancer, lymphoma and / or multiple myeloma; and the hematological tumors include leukemia.
[0026] Furthermore, the CD3ζITAM domain of the CAR-T cell portion is used to appropriately activate T cell downstream signals.
[0027] Beneficial technical effects
[0028] The CAR structure provided by the present invention is a new miniaturized second-generation CAR structure. The new miniaturized second-generation CAR structure is short (both the extracellular segment and the intracellular segment are relatively short); the expression level is high, which can be increased by about 2 times compared to ordinary CAR; it can also efficiently activate the killing effect of CAR-T cells on tumor cells. At a low efficiency target ratio (effective target ratio 1: 1), the 24-hour killing activity can be increased by about 7 times; the starting time of the killing effect is short, and at an effective target ratio of 5: 1, killing can occur as early as about 6 hours. In addition, the use of hinge regions or transmembrane regions from different molecular sources does not affect the killing activity of the new miniaturized second-generation CAR. The above shows that the new miniaturized second-generation CAR provided by the present invention can significantly improve the effectiveness of treatment.
[0029] Specifically, the protein sequence length of the CAR structure provided by the present invention is less than 300 amino acids, and part of the CD3ζ signaling domain is only connected to an intracellular co-stimulatory molecule (e.g., 4-1BB). The present invention proves that this miniaturized CAR can have a good killing effect on a variety of tumors (including solid tumors and hematological tumors). The CD3ζ signaling domain includes CD3ζITAM1, ITAM2, and ITAM3. Currently, there are no reports on CARs synthesized using only a single CD3ζITAM domain and CAR-T cells prepared therefrom having good killing effects in targeting solid tumors. Therefore, the present invention is groundbreaking. The present invention has experimentally verified that CAR-T synthesized using only a single CD3ζITAM1 has a good tumor killing effect, but this is only an example, not a limitation.
[0030] Finally, the CAR-T cells of the present invention retain only a single CD3ζ ITAM domain, which has been shown to be sufficient to activate T cell downstream signals, promoting the effective killing of tumor cells by CAR-T cells. In addition, part of the CD3ζ signaling domain can prevent excessive activation of T cell downstream signals from damaging CAR-T cells, thereby better exerting tumor killing effects. Therefore, the CAR-T cells prepared by the present invention not only have effective killing ability, but also have good killing persistence. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be derived from these drawings without inventive effort.
[0032] FIG1 is a schematic diagram of the structure of the novel miniaturized CAR synthesized by the present invention;
[0033] FIG2 is a graph showing the positive expression rate of HER2 CAR synthesized in one embodiment of the present invention (APC is a fluorescent dye, H represents height; the horizontal axis represents fluorescence intensity);
[0034] FIG3 is a diagram showing the effect of HER2 CAR-T cells killing (LDH) in vitro in one embodiment of the present invention;
[0035] FIG4 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2 CAR-T cells at a 1:1 effector-target ratio for 24 hours in one embodiment of the present invention (magnification 100x);
[0036] FIG5 is a graph showing the continuous killing of SKOV3-mCherry tumor cells and HER2 CAR-T cells at an effector-target ratio of 1:1 in one embodiment of the present invention;
[0037] FIG6 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2 CAR-T cells at an effector-target ratio of 1:2.5 for 24 hours in one embodiment of the present invention (magnification 100x);
[0038] FIG7 is a curve chart showing the continuous killing of SKOV3-mCherry tumor cells and HER2 CAR-T cells at an effector-target ratio of 1:2.5 in one embodiment of the present invention;
[0039] FIG8 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2 CAR-T cells at an effector-target ratio of 1:5 for 24 hours in one embodiment of the present invention (magnification 100x);
[0040] FIG9 is a graph showing the continuous killing of SKOV3-mCherry tumor cells and HER2 CAR-T cells at an effector-target ratio of 1:5 in one embodiment of the present invention;
[0041] FIG10 is a graph showing the positive expression rate of the CLDN 18.2 CAR synthesized in one embodiment of the present invention (PE is a fluorescent dye, A represents area, and the abscissa represents fluorescence intensity);
[0042] FIG11 is a diagram showing the in vitro killing (LDH) effect of CLDN 18.2 CAR-T cells in one embodiment of the present invention;
[0043] FIG12 is a diagram showing the killing effect of SKOV3-mCherry-CLDN 18.2 tumor cells and CLDN 18.2 CAR-T cells at a 1:1 effector-target ratio for 24 hours in one embodiment of the present invention (magnification: 100x);
[0044] FIG13 is a graph showing the continuous killing of SKOV3-mCherry-CLDN 18.2 tumor cells and CLDN 18.2 CAR-T cells at an effector-target ratio of 1:1 in one embodiment of the present invention;
[0045] FIG14 is a diagram showing the killing effect of SKOV3-mCherry-CLDN 18.2 tumor cells and CLDN 18.2 CAR-T cells at an effector-target ratio of 1:2.5 for 24 hours in one embodiment of the present invention (magnification: 100x);
[0046] FIG15 is a graph showing the continuous killing of SKOV3-mCherry-CLDN 18.2 tumor cells and CLDN 18.2 CAR-T cells at an effector-target ratio of 1:2.5 in one embodiment of the present invention;
[0047] FIG16 is a diagram showing the killing effect of SKOV3-mCherry-CLDN 18.2 tumor cells and CLDN 18.2 CAR-T cells at an effector-target ratio of 1:5 for 24 hours in one embodiment of the present invention (magnification 100x);
[0048] FIG17 is a graph showing the continuous killing of SKOV3-mCherry-CLDN 18.2 tumor cells and CLDN 18.2 CAR-T cells at an effector-target ratio of 1:5 in one embodiment of the present invention;
[0049] FIG18 is a graph showing the positive expression rate of BCMA CAR synthesized in one embodiment of the present invention (APC is a fluorescent dye, A represents area, and the abscissa represents fluorescence intensity);
[0050] FIG19 is a diagram showing the in vitro killing (LDH) effect of BCMA CAR-T cells in one embodiment of the present invention;
[0051] FIG20 is a diagram showing the killing effect of MM1S-mCherry tumor cells and BCMA CAR-T cells at an effector-target ratio of 1:2.5 for 24 hours in one embodiment of the present invention (magnification 100x);
[0052] FIG21 is a graph showing the continuous killing of MM1S-mCherry tumor cells and BCMA CAR-T cells at an effector-target ratio of 1:2.5 in one embodiment of the present invention;
[0053] FIG22 is a diagram showing the killing effect of MM1S-mCherry tumor cells and BCMA CAR-T cells at an effector-target ratio of 1:5 for 24 hours in one embodiment of the present invention (magnification 100x);
[0054] FIG23 is a graph showing the continuous killing of MM1S-mCherry tumor cells and BCMA CAR-T cells at an effector-target ratio of 1:5 in one embodiment of the present invention;
[0055] FIG24 is a diagram showing the killing effect of MM1S-mCherry tumor cells and BCMA CAR-T cells at an effector-target ratio of 1:10 for 24 hours in one embodiment of the present invention (magnification 100x);
[0056] FIG25 is a graph showing the continuous killing of tumor cells by MM1S-mCherry and BCMA CAR-T cells at an effector-target ratio of 1:10 in one embodiment of the present invention;
[0057] Figure 26 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2CAR-T cells (with different transmembrane regions and hinge regions) at effector-target ratios of 1:2.5 and 1:5 for 24 hours in one embodiment of the present invention (magnification 100 times).
[0058] FIG27 is a graph showing the positive expression rates of HER2 CARs with different structural designs synthesized in one embodiment of the present invention (APC is a fluorescent dye, H represents height; the abscissa represents fluorescence intensity);
[0059] FIG28 is a diagram showing the in vitro killing (LDH) effects of HER2 CAR-T cells with different structural designs according to one embodiment of the present invention;
[0060] FIG29 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2 CAR-T cells with different structural designs at a 1:1 effector-target ratio for 24 hours in one embodiment of the present invention (magnification: 100x);
[0061] FIG30 is a graph showing the continuous killing of SKOV3-mCherry tumor cells and HER2 CAR-T cells with different structural designs at a 1:1 effector-target ratio in one embodiment of the present invention;
[0062] FIG31 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2 CAR-T cells with different structural designs at an effector-target ratio of 1:2.5 for 24 hours in one embodiment of the present invention (magnification: 100x);
[0063] FIG32 is a graph showing the continuous killing of SKOV3-mCherry tumor cells and HER2 CAR-T cells with different structural designs at an effector-target ratio of 1:2.5 in one embodiment of the present invention;
[0064] FIG33 is a diagram showing the killing effect of SKOV3-mCherry tumor cells and HER2 CAR-T cells with different structural designs at an effector-target ratio of 1:5 for 24 hours in one embodiment of the present invention (magnification: 100x);
[0065] FIG34 is a graph showing the continuous killing of SKOV3-mCherry tumor cells and HER2 CAR-T cells with different structural designs at an effector-target ratio of 1:5 in one embodiment of the present invention. DETAILED DESCRIPTION
[0066] To make the purpose, technical solutions, and advantages of the embodiments of the present invention more clear, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.
[0067] As used herein, "and / or" includes any and all combinations of one or more of the associated listed items.
[0068] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.
[0069] It should be noted that, in this document, the terms "comprises," "includes," or any other variations thereof are intended to encompass non-exclusive inclusion, such that a process, method, article, or apparatus comprising a series of elements includes not only those elements but also other elements not explicitly listed, or elements inherent to such process, method, article, or apparatus. In the absence of further limitations, an element defined by the phrase "comprising a ..." does not exclude the presence of other identical elements in the process, method, article, or apparatus comprising the element.
[0070] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.
[0071] In this specification, some embodiments may be disclosed in a format of being within a certain range. It should be understood that such description of "being within a certain range" is only for convenience and brevity and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of a range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the range The description of should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within this range, for example, 1, 2, 3, 4, 5, and 6. The above rules apply regardless of the breadth of the range.
[0072] The "appropriate activation" mentioned in the present invention refers to the effective activation of T cell downstream signals, so that CAR-T cells can effectively kill tumor cells; but at the same time, it avoids excessive activation of T cell downstream signals, thereby damaging the CAR-T cells themselves.
[0073] Example 1
[0074] This example provides an example of a method for preparing CAR-T cells.
[0075] 1. Construction of CAR expression vector
[0076] 1) The CAR structure consists of an extracellular HER2 nanobody, a CD8 hinge region, a CD8 transmembrane region, an intracellular co-stimulatory molecule (4-1BB), and a partial CD3ζ signaling domain (CD3ζITAM1) / CD3ζ full-length domain (control). The structural fragments were prepared by gene synthesis.
[0077] It is understood that the extracellular nanobodies optionally include various nanobodies targeting solid tumors or hematological tumors. The nanobodies shown in the following examples are only examples, not limitations. In this embodiment, nanobodies targeting HER2 are used as examples.
[0078] 2) The Pwpxld vector and CAR structural fragment were double-digested with restriction endonucleases EcoR I and BamH I, respectively, and then ligated with T4 ligase for transformation and screening culture. The obtained positive clones were sequenced and identified to finally obtain Her2 VH-BBZ (short) -Pwpxld expression vector and Her2VH-BBZ (full) - Pwpxld control vector (containing full-length CD3ζ).
[0079] The structure of the CAR of the present invention is shown in FIG1 .
[0080] The sequences of the fragments synthesized / amplified in this example are shown in Table 1.
[0081] Table 1
[0082] 2. Lentiviral Packaging
[0083] 1) Resuscitate and culture 293T cells, and perform virus packaging when the confluency reaches about 80%.
[0084] 2) Add chloroquine solution according to the amount of culture medium (DMEM + 10% FBS) to make the final concentration 100 μmol / L.
[0085] 3) Virus packaging system (10 cm culture dish): 50 μl CaCl2, 20 μg constructed core plasmid, 10 μg Pspax2, 5 μg PMD2.0G, 500 μl nuclease-free water, 500 μl 2X BBS.
[0086] 4) After about 10 hours, replace with fresh pre-warmed culture medium (DMEM + 10% FBS).
[0087] 5) The virus fluids cultured for 48 h and 72 h were collected and filtered through a 0.22 μm filter to remove impurities.
[0088] 6) Ultracentrifuge and resuspend the concentrated virus in DPBS at a 1 / 400 ratio of the viral stock solution. Aliquot according to subsequent use and freeze at -80°C until use.
[0089] 3. Peripheral Blood Cell Isolation
[0090] 1) Incubate T cell culture flasks (T25) one day in advance and incubate overnight at 4°C. T cell culture medium contains anti-human CD3 and CD28 monoclonal antibodies: 3 ml DPBS, 4 μg / mL CD3, and 2 μg / mL CD28.
[0091] 2) Draw an appropriate amount of fresh blood from healthy volunteers.
[0092] 3) Take a 15 mL BD tube, add 5 mL of Ficoll, and gently add 5 mL of fresh blood.
[0093] 4) Centrifuge at room temperature, 1000 g (centrifuge acceleration, 1 step up, 1 step down), for 30 min.
[0094] 5) After centrifugation, carefully aspirate the peripheral blood lymphocytes in the middle layer (white).
[0095] 6) Add three times the volume of pre-warmed DPBS for washing, 300g, 10min.
[0096] 7) Optionally, add 5 mL of red blood cell lysis buffer, lyse at room temperature for 5 minutes, and add an equal volume of pre-warmed DPBS.
[0097] 8) Count cells and centrifuge at room temperature, 100g, for 10 min.
[0098] 9) Add appropriate amount of T cell culture medium (X-vivo, 5% AB serum, 400 IU IL-2) to resuspend the cells at 2*10^6 / mL.
[0099] 10) Aspirate the antibody incubation solution in the T25 flask, add T cell culture medium to resuspend the T cells, and culture them at 37°C for about 48 hours.
[0100] 4. CAR-T Cell Preparation
[0101] 1) Incubate the T cell culture plate one day in advance and incubate overnight at 4°C. Use a 24-well plate and add 0.5 ml of DPBS and 10 μl of RetroNectin (1 mg / mL) to each well.
[0102] 2) Aspirate the RetroNectin solution.
[0103] 3) Add 1 mL of 2% BSA solution to each well and block at 37°C for 30 minutes.
[0104] 4) Remove the blocking solution and wash once with DPBS.
[0105] 5) Add 200 μl of 400X virus and 300 μl of X-vivo complete medium to each well (non-adherent plate) and centrifuge at 32°C, 1000 g (centrifuge acceleration, 2 up / 2 down) for 2 h.
[0106] 6) Add 2-2.5*10^6 T cells activated for approximately 48 hours to each well, add X-vivo complete medium to 1 mL / well, and centrifuge at 32°C, 300g (centrifuge acceleration, 2 up / 2 down) for 15 minutes.
[0107] The miniaturized CAR-T cells synthesized in this example are referred to as Her2 VH-BBZ. (short) The full-length control CAR-T is referred to as Her2 VH-BBZ (full) .
[0108] 7) After culturing at 37℃ for about 72 hours, the positive expression rate of CAR in the experimental group and the control group was detected by flow cytometry, as shown in Figure 2. The results showed that Her2 VH-BBZ (short) The positive expression rate of Her2 VH-BBZ was 76.0%; (full) The positive expression rate was 60.9%.
[0109] Example 2
[0110] This example provides an in vitro killing assay of the CAR-T cells synthesized in Example 1.
[0111] 1) 96-well plate killing: 1*10^4 tumor cells / well, using the CAR-T cells synthesized in Example 1 of the present invention, and incubated with tumor cells at effector-target ratios (effector cell: target cell = CAR-T: tumor cell) of 1:1, 2.5:1, and 5:1, respectively. Each effector-target ratio has 3 replicates, and blank T cells (Mock) are used as a control.
[0112] This example uses the human ovarian cancer cell line Skov3-mCherry, which is a widely representative cell model.
[0113] 2) Use a live cell dynamic detector to continuously detect the in vitro killing activity of CAR-T cells in the experimental and control groups.
[0114] 3) After incubation for about 24 hours, the culture supernatant was collected to detect LDH and calculate the tumor lysis rate.
[0115] The experimental results are shown in Figures 3 to 9.
[0116] Figure 3 shows that both the miniaturized CAR-T and the control CAR-T synthesized in Example 1 can effectively kill HER2 positive tumor cells, but Her2 VH-BBZ (short) CAR-T has a significantly better tumor killing ability, and its killing effect is significantly better than Her2 VH-BBZ when the effector-target ratio E:T=1:1 (full)CAR-T; when the effect-target ratio E:T=5:1, it showed an explosive killing effect. The same effect was achieved with Her2 VH-BBZ at the same effect-target ratio. (full) Not observed in CAR-T.
[0117] Specifically, Figures 4 to 9 show the continuous killing effect under different effector-target ratios. It can be seen that, taking the effector-target ratio E:T = 1:1 (E stands for Effector cell, i.e., effector cell; T stands for Target cell, i.e., tumor cell) as an example, continuous killing for 24 hours, Her2 VH-BBZ (short) CAR-T and Her2 VH-BBZ (full) The killing effect of CAR-T was not much different, but after 24 hours, Her2 VH-BBZ (short) The killing effect of CAR-T is gradually better than that of Her2 VH-BBZ (full) The trend of CAR-T cells is most evident after 48 hours of continuous killing. This indicates that a single CD3ζITAM (CD3ζITAM1) signaling domain is sufficient to activate T cell downstream signaling, promoting the effective killing of tumor cells by CAR-T cells, while also avoiding damage to CAR-T cells caused by excessive activation of T cell downstream signaling, thereby achieving better sustained tumor killing.
[0118] Example 3
[0119] This example provides another example of a method for preparing CAR-T cells.
[0120] 1. Construction of CAR expression vector
[0121] 1) The CAR structure consists of an extracellular CLDN18.2 nanobody, a CD8 hinge region, a CD8 transmembrane region, an intracellular co-stimulatory molecule (4-1BB), and a partial CD3ζ signaling domain (CD3ζITAM1) / CD3ζ full-length domain (control). The structural fragments were prepared by gene synthesis.
[0122] In this example, a nanobody targeting CLDN18.2 is used as an example.
[0123] 2) The Pwpxld vector and CAR structural fragment were double-digested with restriction endonucleases EcoR I and BamH I, respectively, and then ligated with T4 ligase for transformation and screening culture. The obtained positive clones were sequenced and identified to finally obtain CLDN18.2 VH-BBZ (short) -Pwpxld expression vector and CLDN18.2VH-BBZ (full) - Pwpxld control vector (containing full-length CD3ζ).
[0124] The sequences of the fragments synthesized / amplified in this example are shown in Table 2.
[0125] Table 2
[0126] 2. Lentiviral Packaging
[0127] 1) Resuscitate and culture 293T cells, and perform virus packaging when the confluency reaches about 80%.
[0128] 2) Add chloroquine solution according to the amount of culture medium (DMEM + 10% FBS) to make the final concentration 100 μmol / L.
[0129] 3) Virus packaging system (10 cm culture dish): 50 μl CaCl2, 20 μg constructed core plasmid, 10 μg Pspax2, 5 μg PMD2.0G, 500 μl nuclease-free water, 500 μl 2X BBS.
[0130] 4) After about 10 hours, replace with fresh pre-warmed culture medium (DMEM + 10% FBS).
[0131] 5) The virus fluids cultured for 48 h and 72 h were collected and filtered through a 0.22 μm filter to remove impurities.
[0132] 6) Ultracentrifuge and resuspend the concentrated virus in DPBS at a 1 / 400 ratio of the viral stock solution. Aliquot according to subsequent use and freeze at -80°C until use.
[0133] 3. Peripheral Blood Cell Isolation
[0134] 1) Incubate T cell culture flasks (T25) one day in advance and incubate overnight at 4°C. T cell culture medium contains anti-human CD3 and CD28 monoclonal antibodies: 3 ml DPBS, 4 μg / mL CD3, and 2 μg / mL CD28.
[0135] 2) Draw an appropriate amount of fresh blood from healthy volunteers.
[0136] 3) Take a 15 mL BD tube, add 5 mL of Ficoll, and gently add 5 mL of fresh blood.
[0137] 4) Centrifuge at room temperature, 1000 g (centrifuge acceleration, 1 step up, 1 step down), for 30 min.
[0138] 5) After centrifugation, carefully aspirate the peripheral blood lymphocytes in the middle layer (white).
[0139] 6) Add three times the volume of pre-warmed DPBS for washing, 300g, 10min.
[0140] 7) Optionally, add 5 mL of red blood cell lysis buffer, lyse at room temperature for 5 minutes, and add an equal volume of pre-warmed DPBS.
[0141] 8) Count cells and centrifuge at room temperature, 100g, for 10 min.
[0142] 9) Add appropriate amount of T cell culture medium (X-vivo, 5% AB serum, 400 IU IL-2) to resuspend the cells at 2*10^6 / mL.
[0143] 10) Aspirate the antibody incubation solution in the T25 flask, add T cell culture medium to resuspend the T cells, and culture them at 37°C for about 48 hours.
[0144] 4. CAR-T Cell Preparation
[0145] 1) Incubate the T cell culture plate one day in advance and incubate overnight at 4°C. Use a 24-well plate and add 0.5 ml of DPBS and 10 μl of RetroNectin (1 mg / mL) to each well.
[0146] 2) Aspirate the RetroNectin solution.
[0147] 3) Add 1 mL of 2% BSA solution to each well and block at 37°C for 30 minutes.
[0148] 4) Remove the blocking solution and wash once with DPBS.
[0149] 5) Add 200 μl of 400X virus and 300 μl of X-vivo complete medium to each well (non-adherent plate) and centrifuge at 32°C, 1000 g (centrifuge acceleration, 2 up / 2 down) for 2 h.
[0150] 6) Add 2-2.5*10^6 T cells activated for approximately 48 hours to each well, add X-vivo complete medium to 1 mL / well, and centrifuge at 32°C, 300g (centrifuge acceleration, 2 up / 2 down) for 15 minutes.
[0151] The CAR-T cells synthesized in this example are referred to as CLDN18.2 VH-BBZ (short) The control group CAR-T is referred to as CLDN18.2 VH-BBZ (full) .
[0152] 7) Cultured at 37°C for about 72 hours, the CAR positive expression rate of the experimental and control groups was detected by flow cytometry, as shown in Figure 10. The results showed that CLDN18.2 VH-BBZ (short) The positive expression rate of CLDN18.2VH-BBZ was 85.1%; (full)The positive expression rate was 50.5%.
[0153] Example 4
[0154] This example provides an in vitro killing assay for the CAR-T cells synthesized in Example 3.
[0155] 1) 96-well plate killing: Tumor cells 1*10^4 / well, using the CAR-T cells synthesized in Example 3, were plated and co-incubated with CAR-T cells and tumor cells at effector-target ratios of 1:1, 2.5:1, and 5:1, respectively. Each effector-target ratio had 3 replicates, and blank T cells (Mock) were used as a control.
[0156] This example uses the Skov3-mCherry-Claudin18.2 cell line, which is a cell model that overexpresses Claudin18.2 (CLDN18.2).
[0157] 2) Use a live cell dynamic detector to continuously detect the in vitro killing of CAR-T cells in the experimental and control groups.
[0158] 3) After incubation for about 24 hours, the culture supernatant was collected to detect LDH and calculate the tumor lysis rate.
[0159] The experimental results are shown in Figures 11 to 17.
[0160] Figure 11 shows that the miniaturized CAR-T synthesized in Example 3 and the full-length CAR-T in the control group can effectively kill tumor cells expressing CLDN18.2, but CLDN18.2 VH-BBZ (short) CAR-T has significantly better tumor killing ability, and its effector-target ratio E:T=1:1 is significantly better than CLDN18.2 VH-BBZ. (full) CAR-T; and this tumor killing advantage can still be maintained when the effector-target ratio E:T=2.5:1 and E:T=5:1.
[0161] Specifically, Figures 12 to 17 show the continuous killing effect under different effector-target ratios. It can be seen that when the effector-target ratio E:T = 1:1 (E stands for effector cell, i.e., effector cell; T stands for target cell, i.e., tumor cell), continuous killing for 24 hours, CLDN18.2 VH-BBZ (short) The killing effect of CAR-T is significantly better than that of CLDN18.2 VH-BBZ (full) CAR-T, and this killing advantage gradually increases over time. Compared with CLDN18.2 VH-BBZ (full)CAR-T, when the effector-target ratio E:T = 2.5:1, continuous killing for 10 hours, and when the effector-target ratio E:T = 5:1, continuous killing for 8 hours, CLDN18.2 VH-BBZ (short) CAR-T cells exhibit significantly better killing advantages. This suggests that a single CD3ζITAM (CD3ζITAM1) signaling domain is sufficient to activate T cell downstream signaling, promoting the effective killing of tumor cells by CAR-T cells while avoiding damage to CAR-T cells caused by excessive activation of T cell downstream signaling, thereby achieving better tumor killing sustainability.
[0162] Example 5
[0163] This example provides another example of a method for preparing CAR-T cells.
[0164] 1. Construction of CAR expression vector
[0165] 1) The CAR structure consists of an extracellular BCMA nanobody, a CD8 hinge region, a CD8 transmembrane region, an intracellular co-stimulatory molecule (4-1BB), and a partial CD3ζ signaling domain (CD3ζITAM1) / CD3ζ full-length domain (control). The structural fragments were prepared by gene synthesis.
[0166] In this example, nanoantibodies targeting BCMA are used as an example.
[0167] 2) The Pwpxld vector and CAR structural fragment were double-digested with restriction endonucleases EcoR I and BamH I, respectively, and then ligated with T4 ligase for transformation and screening culture. The obtained positive clones were sequenced and identified to finally obtain BCMA VH-BBZ (short) -Pwpxld expression vector and BCMA VH-BBZ (full) - Pwpxld control vector (containing full-length CD3ζ).
[0168] The sequences of the fragments synthesized / amplified in this example are shown in Table 3.
[0169] Table 3
[0170] 2. Lentiviral Packaging
[0171] 1) Resuscitate and culture 293T cells, and perform virus packaging when the confluency reaches about 80%.
[0172] 2) Add chloroquine solution according to the amount of culture medium (DMEM + 10% FBS) to make the final concentration 100 μmol / L.
[0173] 3) Virus packaging system (10 cm culture dish): 50 μl CaCl2, 20 μg constructed core plasmid, 10 μg Pspax2, 5 μg PMD2.0G, 500 μl nuclease-free water, 500 μl 2X BBS.
[0174] 4) After about 10 hours, replace with fresh pre-warmed culture medium (DMEM + 10% FBS).
[0175] 5) The virus fluids cultured for 48 h and 72 h were collected and filtered through a 0.22 μm filter to remove impurities.
[0176] 6) Ultracentrifuge and resuspend the concentrated virus in DPBS at a 1 / 400 ratio of the viral stock solution. Aliquot according to subsequent use and freeze at -80°C until use.
[0177] 3. Peripheral Blood Cell Isolation
[0178] 1) Incubate T cell culture flasks (T25) one day in advance and incubate overnight at 4°C. T cell culture medium contains anti-human CD3 and CD28 monoclonal antibodies: 3 ml DPBS, 4 μg / mL CD3, and 2 μg / mL CD28.
[0179] 2) Draw an appropriate amount of fresh blood from healthy volunteers.
[0180] 3) Take a 15 mL BD tube, add 5 mL of Ficoll, and gently add 5 mL of fresh blood.
[0181] 4) Centrifuge at room temperature, 1000 g (centrifuge acceleration, 1 step up, 1 step down), for 30 min.
[0182] 5) After centrifugation, carefully aspirate the peripheral blood lymphocytes in the middle layer (white).
[0183] 6) Add three times the volume of pre-warmed DPBS for washing, 300g, 10min.
[0184] 7) Optionally, add 5 mL of red blood cell lysis buffer, lyse at room temperature for 5 minutes, and add an equal volume of pre-warmed DPBS.
[0185] 8) Count cells and centrifuge at room temperature, 100g, for 10 min.
[0186] 9) Add appropriate amount of T cell culture medium (X-vivo, 5% AB serum, 400 IU IL-2) to resuspend the cells at 2*10^6 / mL.
[0187] 10) Aspirate the antibody incubation solution in the T25 flask, add T cell culture medium to resuspend the T cells, and culture them at 37°C for about 48 hours.
[0188] 4. CAR-T Cell Preparation
[0189] 1) Incubate the T cell culture plate one day in advance and incubate overnight at 4°C. Use a 24-well plate and add 0.5 ml of DPBS and 10 μl of RetroNectin (1 mg / mL) to each well.
[0190] 2) Aspirate the RetroNectin solution.
[0191] 3) Add 1 mL of 2% BSA solution to each well and block at 37°C for 30 minutes.
[0192] 4) Remove the blocking solution and wash once with DPBS.
[0193] 5) Add 200 μl of 400X virus and 300 μl of X-vivo complete medium to each well (non-adherent plate) and centrifuge at 32°C, 1000 g (centrifuge acceleration, 2 up / 2 down) for 2 h.
[0194] 6) Add 2-2.5*10^6 T cells activated for approximately 48 hours to each well, add X-vivo complete medium to 1 mL / well, and centrifuge at 32°C, 300g (centrifuge acceleration, 2 up / 2 down) for 15 minutes.
[0195] The CAR-T cells synthesized in this example are referred to as BCMA VH-BBZ (short) The control group CAR-T is referred to as BCMA VH-BBZ (full) .
[0196] 7) Cultured at 37°C for about 72 hours, the CAR positive expression rate of the experimental group and the control group was detected by flow cytometry, as shown in Figure 18. The results showed that BCMA VH-BBZ (short) The positive expression rate of BCMA VH-BBZ was 76.6%; (full) The positive expression rate was 33.7%.
[0197] Example 6
[0198] This example provides an in vitro killing assay for the CAR-T cells synthesized in Example 5.
[0199] 1) 96-well plate killing: 1*10^4 tumor cells / well, using the CAR-T cells synthesized in Example 5, respectively, according to the CAR-T cell and tumor cell target ratio of 2.5:1, 5:1, and 10:1, respectively, plated and co-incubated, with 3 replicates for each target ratio, and blank T cell (Mock) control was performed. After about 24 hours, the culture supernatant was collected to detect LDH to calculate the tumor lysis rate.
[0200] This example uses the human multiple myeloma cell line MM1S-mCherry, which is a widely representative cell model.
[0201] 2) A live cell dynamics detector was used to continuously monitor the in vitro killing activity of CAR-T cells in the experimental and control groups. CAR-T cells were plated and co-incubated with tumor cells at effector-target ratios of 2.5:1, 5:1, and 10:1, with three replicate wells for each effector-target ratio.
[0202] The experimental results are shown in Figures 19 to 25.
[0203] Figure 19 shows that both the CAR-T synthesized in Example 5 and the control group CAR-T can effectively kill BCMA-positive tumor cells, but the miniaturized BCMA VH-BBZ (short) CAR-T has significantly better tumor killing ability at an efficient target ratio, and is slightly better than BCMA VH-BBZ at an effector-target ratio of E:T=5:1. (full) CAR-T; however, when the effect-target ratio E:T=10:1, it is significantly better than BCMA VH-BBZ (full) CAR-T.
[0204] Specifically, Figures 20 to 25 show the continuous killing effect under different effector-target ratios. It can be seen that when the effector-target ratio E:T=10:1 (E stands for Effector cell, i.e., effector cell; T stands for Target cell, i.e., tumor cell), the BCMA VH-BBZ (short) CAR-T and BCMA VH-BBZ (full) The killing effect of CAR-T was not much different, but after 7 hours, BCMA VH-BBZ (short) The killing effect of CAR-T is gradually better than that of BCMA VH-BBZ (full) The trend of CAR-T. Taking the effector-target ratio E:T=5:1 as an example, the killing lasts for 9 hours, BCMA VH-BBZ (short) CAR-T and BCMA VH-BBZ (full) The effect of CAR-T is not much different, but BCMA VH-BBZ (short) The killing effect of CAR-T is gradually better than that of BCMA VH-BBZ (full) This indicates that a single CD3ζITAM (CD3ζITAM1) signaling domain is sufficient to activate T cell downstream signals, promoting the effective killing of tumor cells by CAR-T cells, while avoiding damage to CAR-T cells caused by excessive activation of T cell downstream signals, thereby achieving better tumor killing sustainability.
[0205] Examples 1-6 provide different examples of miniaturized second-generation CAR structures, wherein the smallest CAR has 281 amino acids and the largest CAR has 294 amino acids.
[0206] Example 7
[0207] This example provides three other examples of methods for preparing CAR-T cells.
[0208] 1. Construction of CAR expression vector
[0209] 1) The CAR structure consists of an extracellular HER2 nanobody, a CD28 hinge region, a CD28 transmembrane region or a CD28 hinge region, a CD3 transmembrane region or a CD8 hinge region, a CD3 transmembrane region, an intracellular co-stimulatory molecule (4-1BB), and a partial CD3ζ signaling domain (CD3ζITAM1) / CD3ζ full-length domain (control). The structural fragments are prepared by gene synthesis.
[0210] It is understood that the extracellular nanobodies optionally include various nanobodies targeting solid tumors or hematological tumors. The nanobodies shown in the following examples are only examples, not limitations. In this embodiment, nanobodies targeting HER2 are used as examples.
[0211] 2) The Pwpxld vector and CAR structural fragment were double-digested with restriction endonucleases EcoR I and BamH I, respectively, and then ligated with T4 ligase for transformation and screening culture. The obtained positive clones were sequenced and identified to finally obtain Her2-28H+28TM-VH-BBZ (short) -Pwpxld,Her2-28H+3TM-VH-BBZ (short) -Pwpxld and Her2-8H+3TM-VH-BBZ (short) -Pwpxld expression vector.
[0212] The structure of the CAR of the present invention is shown in FIG1 .
[0213] The sequences of the fragments synthesized / amplified in this example are shown in Tables 4-6.
[0214] Table 4 Her2-28H+28TM-VH-BBZ (short)
[0215] Table 5 Her2-28H+3TM-VH-BBZ (short)
[0216] Table 6 Her2-8H+3TM-VH-BBZ (short)
[0217] 2. Lentiviral Packaging
[0218] 1) Resuscitate and culture 293T cells, and perform virus packaging when the confluency reaches about 80%.
[0219] 2) Add chloroquine solution according to the amount of culture medium (DMEM + 10% FBS) to make the final concentration 100 μmol / L.
[0220] 3) Virus packaging system (10 cm culture dish): 50 μl CaCl2, 20 μg constructed core plasmid, 10 μg Pspax2, 5 μg PMD2.0G, 500 μl nuclease-free water, 500 μl 2X BBS.
[0221] 4) After about 10 hours, replace with fresh pre-warmed culture medium (DMEM + 10% FBS).
[0222] 5) The virus fluids cultured for 48 h and 72 h were collected and filtered through a 0.22 μm filter to remove impurities.
[0223] 6) Ultracentrifuge and resuspend the concentrated virus in DPBS at a 1 / 400 ratio of the viral stock solution. Aliquot according to subsequent use and freeze at -80°C until use.
[0224] 3. Peripheral Blood Cell Isolation
[0225] 1) Incubate T cell culture flasks (T25) one day in advance and incubate overnight at 4°C. T cell culture medium contains anti-human CD3 and CD28 monoclonal antibodies: 3 ml DPBS, 4 μg / mL CD3, and 2 μg / mL CD28.
[0226] 2) Draw an appropriate amount of fresh blood from healthy volunteers.
[0227] 3) Take a 15 mL BD tube, add 5 mL of Ficoll, and gently add 5 mL of fresh blood.
[0228] 4) Centrifuge at room temperature, 1000 g (centrifuge acceleration, 1 step up, 1 step down), for 30 min.
[0229] 5) After centrifugation, carefully aspirate the peripheral blood lymphocytes in the middle layer (white).
[0230] 6) Add three times the volume of pre-warmed DPBS for washing, 300g, 10min.
[0231] 7) Optionally, add 5 mL of red blood cell lysis buffer, lyse at room temperature for 5 minutes, and add an equal volume of pre-warmed DPBS.
[0232] 8) Count cells and centrifuge at room temperature, 100g, for 10 min.
[0233] 9) Add appropriate amount of T cell culture medium (X-vivo, 5% AB serum, 400 IU IL-2) to resuspend the cells at 2*10^6 / mL.
[0234] 10) Aspirate the antibody incubation solution in the T25 flask, add T cell culture medium to resuspend the T cells, and culture them at 37°C for about 48 hours.
[0235] 4. CAR-T Cell Preparation
[0236] 1) Incubate the T cell culture plate one day in advance and incubate overnight at 4°C. Use a 24-well plate and add 0.5 ml of DPBS and 10 μl of RetroNectin (1 mg / mL) to each well.
[0237] 2) Aspirate the RetroNectin solution.
[0238] 3) Add 1 mL of 2% BSA solution to each well and block at 37°C for 30 minutes.
[0239] 4) Remove the blocking solution and wash once with DPBS.
[0240] 5) Add 200 μl of 400X virus and 300 μl of X-vivo complete medium to each well (non-adherent plate) and centrifuge at 32°C, 1000 g (centrifuge acceleration, 2 up / 2 down) for 2 h.
[0241] 6) Add 2-2.5*10^6 T cells activated for approximately 48 hours to each well, add X-vivo complete medium to 1 mL / well, and centrifuge at 32°C, 300g (centrifuge acceleration, 2 up / 2 down) for 15 minutes.
[0242] The miniaturized CAR-T cells synthesized in this example are referred to as Her2-28H+28TM-VH-BBZ. (short) or Her2-28H+3TM-VH-BBZ (short) or Her2-8H+3TM-VH-BBZ (short) The full-length control CAR-T is referred to as Her2 VH-BBZ (full) (The hinge and transmembrane regions of the full-length control CAR-T are both derived from the CD8 molecule, also expressed as Her2-8H+8TM-VH-BBZ (full) ).
[0243] 7) Culture the cells at 37°C for approximately 72 hours before conducting an in vitro killing test.
[0244] Example 8
[0245] This example provides an in vitro killing assay for the CAR-T cells synthesized in Example 7.
[0246] 1) Killing in 96-well plates: 1*10^4 tumor cells / well, CAR-T cells synthesized in Example 1 of the present invention were plated and co-incubated with tumor cells at effector-target ratios (effector cell: target cell = CAR-T: tumor cell) of 2.5:1 and 5:1, respectively. Each effector-target ratio had 3 replicates, and blank T cells (Mock) were used as a control.
[0247] This example uses the human ovarian cancer cell line Skov3-mCherry, which is a widely representative cell model.
[0248] 2) A live cell dynamics detector was used to record the in vitro killing activity of CAR-T cells in each experimental group and control group by a single shot at 24 hours of co-incubation. The experimental results are shown in Figure 26.
[0249] Figure 26 shows that the miniaturized CAR-T and control CAR-T synthesized in Example 7 can effectively kill HER2 positive tumor cells, but compared with the control Her2 VH-BBZ (full) Compared (the hinge region and transmembrane region are both derived from the CD8 molecule, also expressed as Her2-8H+8TM-VH-BBZ (full) ), Her2-28H+28TM-VH-BBZ (short) and Her2-8H+3TM-VH-BBZ (short) Significantly better tumor killing ability, Her2-28H+3TM-VH-BBZ (short) The tumor killing ability is slightly better than Her2 VH-BBZ (full) (The hinge and transmembrane regions are derived from the CD8 molecule, also expressed as Her2-8H+8TM-VH-BBZ (full) Specifically, the above results show that the use of hinge regions and transmembrane regions from different sources can all exert the advantageous killing effect of the new miniaturized CAR molecules, which is sufficient to activate the downstream signaling of T cells and achieve the effect of promoting CAR-T cells to effectively kill tumor cells.
[0250] Example 9
[0251] This example provides an example of a method for preparing CAR-T cells.
[0252] 1. Construction of CAR expression vector
[0253] 1) The CAR structure consists of an extracellular HER2 nanobody (VH) / HER2 single-chain antibody (scFv) (control), a CD8 hinge region, a CD8 transmembrane region, an intracellular co-stimulatory molecule (4-1BB), and a partial CD3ζ signaling domain (CD3ζITAM1) / CD3ζ full-length domain (control). The structural fragments were prepared by gene synthesis.
[0254] In this embodiment, CARs with different structures targeting HER2 are used as examples.
[0255] 2) The Pwpxld vector and CAR structural fragment were double-digested with restriction endonucleases EcoR I and BamH I, respectively, and then ligated with T4 ligase for transformation and screening culture. The obtained positive clones were sequenced and identified to finally obtain Her2 scFV-BBZ (short) -Pwpxld, Her2 scFV-BBZ (full) -Pwpxld (containing full-length CD3ζ), Her2 VH-BBZ (short) -Pwpxld expression vector and Her2 VH-BBZ (full) - Pwpxld control vector (containing full-length CD3ζ).
[0256] The structure of the CAR of the present invention is shown in FIG1 .
[0257] The sequences of the fragments synthesized / amplified in this example are shown in the following table.
[0258] Table 7 Her2 scFV-BBZ (short)
[0259] Table 8 Her2 scFV-BBZ (full)
[0260] 2. Lentiviral Packaging
[0261] 1) Resuscitate and culture 293T cells, and perform virus packaging when the confluency reaches about 80%.
[0262] 2) Add chloroquine solution according to the amount of culture medium (DMEM + 10% FBS) to make the final concentration 100 μmol / L.
[0263] 3) Virus packaging system (10 cm culture dish): 50 μl CaCl2, 20 μg constructed core plasmid, 10 μg Pspax2, 5 μg PMD2.0G, 500 μl nuclease-free water, 500 μl 2X BBS.
[0264] 4) After about 10 hours, replace with fresh pre-warmed culture medium (DMEM + 10% FBS).
[0265] 5) The virus fluids cultured for 48 h and 72 h were collected and filtered through a 0.22 μm filter to remove impurities.
[0266] 6) Ultracentrifuge and resuspend the concentrated virus in DPBS at a 1 / 400 ratio of the viral stock solution. Aliquot according to subsequent use and freeze at -80°C until use.
[0267] 3. Peripheral Blood Cell Isolation
[0268] 1) Incubate T cell culture flasks (T25) one day in advance and incubate overnight at 4°C. T cell culture medium contains anti-human CD3 and CD28 monoclonal antibodies: 3 ml DPBS, 4 μg / mL CD3, and 2 μg / mL CD28.
[0269] 2) Draw an appropriate amount of fresh blood from healthy volunteers.
[0270] 3) Take a 15 mL BD tube, add 5 mL of Ficoll, and gently add 5 mL of fresh blood.
[0271] 4) Centrifuge at room temperature, 1000 g (centrifuge acceleration, 1 step up, 1 step down), for 30 min.
[0272] 5) After centrifugation, carefully aspirate the peripheral blood lymphocytes in the middle layer (white).
[0273] 6) Add three times the volume of pre-warmed DPBS for washing, 300g, 10min.
[0274] 7) Optionally, add 5 mL of red blood cell lysis buffer, lyse at room temperature for 5 minutes, and add an equal volume of pre-warmed DPBS.
[0275] 8) Count cells and centrifuge at room temperature, 100g, for 10 min.
[0276] 9) Add appropriate amount of T cell culture medium (X-vivo, 5% AB serum, 400 IU IL-2) to resuspend the cells at 2*10^6 / mL.
[0277] 10) Aspirate the antibody incubation solution in the T25 flask, add T cell culture medium to resuspend the T cells, and culture them at 37°C for about 48 hours.
[0278] 4. CAR-T Cell Preparation
[0279] 1) Incubate the T cell culture plate one day in advance and incubate overnight at 4°C. Use a 24-well plate and add 0.5 ml of DPBS and 10 μl of RetroNectin (1 mg / mL) to each well.
[0280] 2) Aspirate the RetroNectin solution.
[0281] 3) Add 1 mL of 2% BSA solution to each well and block at 37°C for 30 minutes.
[0282] 4) Remove the blocking solution and wash once with DPBS.
[0283] 5) Add 200 μl of 400X virus and 300 μl of X-vivo complete medium to each well (non-adherent plate) and centrifuge at 32°C, 1000 g (centrifuge acceleration, 2 up / 2 down) for 2 h.
[0284] 6) Add 2-2.5*10^6 T cells activated for approximately 48 hours to each well, add X-vivo complete medium to 1 mL / well, and centrifuge at 32°C, 300g (centrifuge acceleration, 2 up / 2 down) for 15 minutes.
[0285] The miniaturized CAR-T cells synthesized in this example are referred to as Her2 scFv-BBZ (full) (containing full-length CD3ζ), Her2 scFv-BBZ (short) , Her2 VH-BBZ (full) (containing full-length CD3ζ) and Her2 VH-BBZ (short) .
[0286] 7) After culturing at 37°C for about 72 hours, the positive expression rate of CAR in the experimental and control groups was detected by flow cytometry, as shown in Figure 27. (full) The positive expression rate of Her2scFv-BBZ was 46.4%; (short) The positive expression rate of Her2 VH-BBZ was 63.2%; (full) The positive expression rate of Her2 VH-BBZ was 52.5%; (short) The positive expression rate was 80.2%.
[0287] Example 10
[0288] This example provides an in vitro killing detection test of the CAR-T synthesized in Example 9.
[0289] 1) 96-well plate killing: 1*10^4 tumor cells / well, using the CAR-T cells synthesized in Example 1 of the present invention, and incubated with tumor cells at effector-target ratios (effector cell: target cell = CAR-T: tumor cell) of 1:1, 2.5:1, and 5:1, respectively. Each effector-target ratio has 3 replicates, and blank T cells (Mock) are used as a control.
[0290] This example uses the human ovarian cancer cell line Skov3-mCherry, which is a widely representative cell model.
[0291] 2) Use a live cell dynamic detector to continuously detect the in vitro killing activity of CAR-T cells in the experimental and control groups.
[0292] 3) After incubation for about 24 hours, the culture supernatant was collected to detect LDH and calculate the tumor lysis rate.
[0293] The experimental results are shown in Figures 28 to 34.
[0294] Figure 28 shows that the CAR-T cells expressing different structural designs synthesized in Example 9 can effectively kill HER2 positive tumor cells, but Her2 VH-BBZ (short) CAR-T has significantly better tumor killing ability, and the killing effect when the effector-target ratio E:T=1:1, 2.5:1 and 5:1 is significantly better than Her2 scFv-BBZ (full) , Her2 scFv-BBZ (short) and Her2 VH-BBZ (full) .
[0295] Specifically, Figures 29 to 34 show the continuous killing effect under different effector-target ratios. It can be seen that when the effector-target ratio E:T = 1:1, 2.5:1 and 5:1 (E stands for Effector cell, i.e., effector cell; T stands for Target cell, i.e., tumor cell), Her2 VH-BBZ can kill the tumor cells continuously for 24 hours. (short) The tumor killing ability of CAR-T is significantly better than that of Her2 scFv-BBZ (full) , Her2 scFv-BBZ (short) and Her2 VH-BBZ (full) , among which Her2 scFv-BBZ (full) The killing effect is the worst. At the effector-target ratio E:T=1:1, Her2 VH-BBZ (short) CAR-T begins to kill cells at around 16 hours; at an effector-target ratio of E:T = 2:1, Her2 VH-BBZ (short) CAR-T begins to kill cells as early as 9 hours; at the effector-target ratio E:T=2:1, Her2 VH-BBZ (short) CAR-T cells start killing cells at around 6 hours, which is earlier than Her2 scFv-BBZ cells. (full) , Her2 scFv-BBZ (sh ort) and Her2 VH-BBZ (full), among which Her2 scFv-BBZ (full) The latest killing time. This shows that the length of the CAR molecule is correlated with the killing effect and killing start time of CAR-T cells. Specifically, the shorter the length of the expressed CAR molecule, the better the killing effect of CAR-T cells and the earlier the killing start time.
[0296] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation methods. The above-mentioned specific implementation methods are merely illustrative and not restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are protected by the present invention.
Claims
1. A novel miniaturized chimeric antigen receptor, comprising an extracellular segment, a transmembrane region and an intracellular segment, characterized in that: The extracellular segment is an antigen binding region and a hinge region, the intracellular segment is a portion of CD3ζ connected in series with a co-stimulatory molecule, the length of the chimeric antigen receptor does not exceed 300 amino acids; the length of the antigen binding region of the extracellular segment does not exceed 150 amino acids; the length of the hinge region and the transmembrane region does not exceed 70 amino acids; the length of the intracellular segment does not exceed 100 amino acids.
2. The chimeric antigen receptor according to claim 1, wherein The portion of CD3ζ is the CD3ζ ITAM domain.
3. The chimeric antigen receptor according to claim 2, wherein The CD3ζITAM domain includes a CD3ζITAM1 domain, a CD3ζITAM2 domain or a CD3ζITAM3 domain.
4. The chimeric antigen receptor according to claim 1, wherein The antigen binding region is an antibody targeting solid tumors or hematological tumor cell targets.
5. The chimeric antigen receptor according to claim 1, wherein The antibodies include single domain antibodies or nanobodies.
6. The chimeric antigen receptor according to claim 1, wherein The co-stimulatory molecule is a single co-stimulatory molecule.
7. The chimeric antigen receptor according to claim 1, wherein The hinge region includes a CD8 hinge region or a CD28 hinge region.
8. The chimeric antigen receptor according to claim 1, wherein The transmembrane region includes a CD8 transmembrane region, a CD28 transmembrane region or a CD3 transmembrane region.
9. The chimeric antigen receptor according to claim 1, wherein The connection modes of the hinge region and the transmembrane region include the connection of the CD8 hinge region and the CD8 transmembrane region, the connection of the CD28 hinge region and the CD28 transmembrane region, the connection of the CD28 hinge region and the CD3 transmembrane region, or the connection of the CD8 hinge region and the CD3 transmembrane region.
10. A CAR-T cell, characterized in that: Expressing the chimeric antigen receptor according to any one of claims 1 to 9.
11. Use of the CAR-T cells as described in claim 10 in the preparation of drugs targeting solid tumors or hematological tumors.
12. Use of the CAR-T cells as described in claim 10 in the preparation of treatments for autoimmune diseases.
13. The use according to claim 11, characterized in that The solid tumors include ovarian cancer, breast cancer, gastric cancer, intestinal cancer, lymphoma and / or multiple myeloma; the blood tumors include leukemia.
14. The use according to claim 11 or 12, characterized in that The CD3ζ portion of the CAR-T cells is used to properly activate T cell downstream signaling.
Citation Information
Patent Citations
Chimeric antigen receptor capable of specifically activating NK cells and application thereof
CN110627909A
Dimer antigen receptors (drs) that bind cd20
CN115461377A
Long-acting double-target chimeric antigen receptor, nucleic acid molecule, recombinant vector, cell and application of long-acting double-target chimeric antigen receptor
CN115925989A
Chimeric antigen receptor T cell targeting BCMA as well as preparation method and application of chimeric antigen receptor T cell
CN116082519A
Novel CAR-T cell targeting HER2 positive tumor as well as preparation method and application of novel CAR-T cell
CN116655805A
